Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucas Hofmeister

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Colloids and Surfaces. B, Biointerfaces|September 26, 2012
Cell interaction study method using novel 3D silica nanoneedle gradient arraysDeepak Rajput, Spencer W Crowder, Lucas Hofmeister, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 15, 2022
A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 YearsCraig I Coleman, Olivia S Costa, Christopher W Brescia, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 4, 2022
Urinary miRNA Profiles in Chronic Kidney Injury-Benefits of Extracellular Vesicle Enrichment and miRNAs as Potential Biomarkers for Renal Fibrosis, Glomerular Injury, and Endothelial DysfunctionBarbara Petzuch, Agnès Bénardeau, Lucas Hofmeister, et al.
Journal of Medical Economics|August 23, 2022
Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysisCarina Blomström Lundqvist, Sara Själander, Luis A Garcia Rodriguez, et al.
European Journal of Heart Failure|March 12, 2026
Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy QuestionnaireYasuhiro Hamatani, Alexander Peikert, Brian L Claggett, et al.
European Heart Journal|May 11, 2026
Viral respiratory tract infections in heart failure: the FINEARTS-HF trialRagnhild Helseth, Brian L Claggett, Ankeet Bhatt, et al.
JAMA Cardiology|July 8, 2026
Finerenone and Blood Pressure in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical TrialJohn W Ostrominski, Brian L Claggett, Ian J Kulac, et al.
JACC. Heart Failure|December 9, 2025
Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection FractionAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
JAMA Cardiology|March 5, 2025
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HFKirsty McDowell, Kieran F Docherty, Ross T Campbell, et al.
Journal of the American College of Cardiology|December 9, 2025
Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 DiabetesJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Colloids and Surfaces. B, Biointerfaces|September 26, 2012
Cell interaction study method using novel 3D silica nanoneedle gradient arraysDeepak Rajput, Spencer W Crowder, Lucas Hofmeister, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 15, 2022
A RIVA-DM Subanalysis Investigating Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Aged Under Versus Over 80 YearsCraig I Coleman, Olivia S Costa, Christopher W Brescia, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|March 4, 2022
Urinary miRNA Profiles in Chronic Kidney Injury-Benefits of Extracellular Vesicle Enrichment and miRNAs as Potential Biomarkers for Renal Fibrosis, Glomerular Injury, and Endothelial DysfunctionBarbara Petzuch, Agnès Bénardeau, Lucas Hofmeister, et al.
Journal of Medical Economics|August 23, 2022
Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysisCarina Blomström Lundqvist, Sara Själander, Luis A Garcia Rodriguez, et al.
European Journal of Heart Failure|March 12, 2026
Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy QuestionnaireYasuhiro Hamatani, Alexander Peikert, Brian L Claggett, et al.
European Heart Journal|May 11, 2026
Viral respiratory tract infections in heart failure: the FINEARTS-HF trialRagnhild Helseth, Brian L Claggett, Ankeet Bhatt, et al.
JAMA Cardiology|July 8, 2026
Finerenone and Blood Pressure in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical TrialJohn W Ostrominski, Brian L Claggett, Ian J Kulac, et al.
JACC. Heart Failure|December 9, 2025
Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection FractionAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
JAMA Cardiology|March 5, 2025
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HFKirsty McDowell, Kieran F Docherty, Ross T Campbell, et al.
Journal of the American College of Cardiology|December 9, 2025
Timing of Cardiovascular and Kidney Benefits With Finerenone in Heart Failure and Chronic Kidney Disease With Type 2 DiabetesJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
Pageof 2